Nippon Shinyaku Co., Ltd. (NPPNY)
ValueMarkers Composite Index
71% below intrinsic value ($0)
Nippon Shinyaku Co., Ltd. (NPPNY) — VMCI valuation read
Composite valuation read on NPPNY: VMCI 73/100 against a Healthcare sector median of 50. The 23-point above-median print is the headline number for Nippon Shinyaku Co., Ltd., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.
Trailing 30-day insider activity for NPPNY: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.
**Investor frame.** Value, quality, risk in three lines on NPPNY: NPPNY trades at 15.0x earnings, 17% below the Healthcare median of 18.0x; ROIC of 13.0% sits 3.0pp above the Healthcare median (10.0%); net debt to EBITDA of 3.3x is the binding constraint on the bear case. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.
NPPNY fell 0.2% over the trailing 7 days, with a -12.3% read on a 30-day basis.
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.